

Table of Content

List of Figures.....	xv
List of Tables.....	xix
Abbreviations.....	xx
Preface.....	xxiii
1. Introduction	1-8
2. Literature Review.....	9-42
2.1. Infection	9
2.2. Biofilm	9
2.2.1. <i>Biofilm formation</i>	9
2.2.2. <i>Quorum sensing</i>	11
2.2.3. <i>Biofilm's components</i>	12
2.2.4. <i>Implication of the Biofilm</i>	13
2.2.5. <i>Mechanism of biofilm resistance for the antibiotics</i>	14
2.2.6. <i>Biofilm forming bacteria</i>	16
2.2.7. <i>Biofilm associated diseases</i>	17
2.3. Biofilm prevention and treatment strategies.....	18
2.3.1. <i>Preventive approaches</i>	18
2.3.2. <i>Treatment strategies to established biofilms</i>	21
2.4. Nanoparticles.....	26
2.4.1. <i>Types of Nanoparticles</i>	27
2.4.2. <i>Role of nanoparticles in the infection and biofilm</i>	29
2.4.3. <i>Research</i>	29

2.5. Burn wound.....	30
2.5.1. <i>Role of the biofilm in the wounds</i>	31
2.5.2. <i>Stages of burn wound healing</i>	32
2.6. Cystic fibrosis.....	33
2.6.1. <i>Cause</i>	33
2.6.2. <i>Sign and symptom</i>	33
2.6.3. <i>Complication</i>	34
2.7. Silver Sulfadiazine.....	36
2.8. Ciprofloxacin.....	39
3. Objective and Hypothesis.....	43
4. Plan of work.....	44-45
5. Chapter 5:	46-73
5.1. Materials.....	46
5.2. Methods.....	46
5.2.1. <i>Analytical method</i>	46
5.2.1.1. <i>Calibration curve of SSD in water</i>	46
5.2.1.2. <i>Calibration curve of SSD in phosphate buffer pH 6.8</i>	47
5.2.2. <i>Preparation of SSD-SLNs</i>	47
5.2.3. <i>Design of formulation experimentation</i>	48
5.2.4. <i>Particle size, polydispersity index and Zeta potential</i>	49
5.2.5. <i>Entrapment efficiency</i>	49
5.2.6. <i>Scanning electron microscopy (SEM)</i>	49

5.2.7. <i>In-vitro</i> release study.....	50
5.2.8. <i>Fourier transform infrared spectroscopy (FT-IR)</i>	50
5.2.9. <i>Differential scanning calorimetric (DSC) study</i>	51
5.2.10. <i>X-ray diffraction (XRD) study</i>	51
5.2.11. <i>Bacterial strain and growth conditions</i>	52
5.2.12. <i>Minimal inhibitory concentration (MIC) assays</i>	52
5.2.13. <i>Anti-Biofilm activity of SSD-SLNs</i>	53
5.2.14. <i>Determination of toxicity on Human Dermal Fibroblast</i>	54
5.2.15. <i>Preparation of SSD-SLNs loaded chitosan gel</i>	54
5.2.16. <i>Texture profile analysis (TPA)</i>	55
5.2.17. <i>In-vivo wound healing studies on rat model</i>	55
5.2.18. <i>Statistical analysis.</i>	56
5.3. Results and Discussion.....	56
5.3.1. <i>Analytical method</i>	56
5.3.2. <i>Optimization of SSD-SLNs and analysis of variables</i>	57
5.3.3. <i>Scanning electron microscopy (SEM)</i>	60
5.3.4. <i>In-vitro drug release study</i>	61
5.3.5. <i>FT-IR</i>	62
5.3.6. <i>Differential scanning calorimetric study</i>	63
5.3.7. <i>XRD study</i>	64
5.3.8. <i>MIC determination</i>	65
5.3.9. <i>Anti-biofilm properties using repeated doses of treatment</i>	66
5.3.10. <i>Determination of toxicity on Human Dermal Fibroblast</i>	69
5.3.11. <i>Texture Profile analysis</i>	70
5.3.12. <i>Comparative wound healing Study</i>	71

6. Chapter 6: Development of Alginate Lyase functionalized Chitosan Nanoparticles of Ciprofloxacin.....	74-107
6.1. Materials	74
6.2. Methods.....	74
6.2.1. Analytical Method.....	74
6.2.2. Fabrication of chitosan nanoparticles.....	75
6.2.3. Preparation of inhalable powder.....	76
6.2.4. In vitro aerodynamic property of dry powder.....	77
6.2.5. Identification of AgLase Conjugation.....	77
6.2.6. Enzyme activity assay of AgLase bearing NPs.....	78
6.2.7. Particle Size (PS), polydispersity index (PDI) and zeta potential (ZP) analysis.....	78
6.2.8. Entrapment efficiency (EE).....	78
6.2.9. Scanning electron microscopy (SEM).....	79
6.2.10. In vitro release.....	79
6.2.11. Fourier transform infrared spectroscopy (FTIR).....	80
6.2.12. X-ray diffraction (XRD).....	80
6.2.13. Collection of mucoid <i>P. aeruginosa</i> , characterization and culture growth.....	80
6.2.14. Minimum inhibitory concentration (MIC)	81
6.2.15. Minimum biofilm inhibitory concentration (MBIC).....	81
6.2.16. Minimum biofilm eradication concentration (MBEC).....	82
6.2.17. Biofilm formation on coverslip and microscopy.....	82
6.2.18. MTT assay.....	83
6.2.19. Haemocompatibility studies.....	83

6.2.19.1. <i>Haemolysis Study</i>	83
6.2.19.2. <i>Platelet aggregation</i>	84
6.2.20. <i>In vivo toxicity study</i>	85
6.2.21. <i>Statistical analysis</i>	86
6.3. Results and Discussion	86
6.3.1. <i>Analytical Method</i>	86
6.3.2. <i>AgLase Conjugation and Enzyme assay</i>	87
6.3.3. <i>Particle characterization (PS, PDI, ZP, and EE)</i>	89
6.3.4. <i>SEM analysis</i>	90
6.3.5. <i>Characterization of Freeze dried powder</i>	91
6.3.6. <i>In vitro release kinetics</i>	91
6.3.7. <i>FT-IR spectra</i>	92
6.3.8. <i>XRD spectra</i>	94
6.3.9. <i>Minimum Inhibitory Concentration</i>	94
6.3.10. <i>Minimum Biofilm Inhibitory concentration (MBIC)</i>	95
6.3.11. <i>Minimum Biofilm Eradication Concentration (MBEC)</i>	98
6.3.12. <i>Microscopic study of biofilm</i>	100
6.3.13. <i>MTT assay</i>	101
6.3.14. <i>Haemolysis</i>	103
6.3.15. <i>Platelet aggregation</i>	104
6.3.16. <i>In vivo toxicity study</i>	107
7. Summary	108-110
8. Conclusion and Future Prospects	111-112
9. References	113-130

10. List of Publications..... 131